MediWound Ltd. (MDWD)

Evaluation: Based on all recent filings, financial statements, and news.

See full evaluation
Ask a question about MediWound Ltd. (MDWD)
Company Performance

Current Price

as of Oct 16, 2024

$17.97

P/E Ratio

N/A

Market Cap

$193.83M

Description

MediWound Ltd. is a biopharmaceutical company, which engages in the development, manufacture, and commercialization of products to address needs in the fields of severe burns, chronic wounds, and other hard-to-heal wounds. Its product NexoBrid, is an orphan biologic for eschar removal in severe burns. The company was founded by Lior Rosenberg and Marian Gorecki in January 2000 and is headquartered in Yavne, Israel.

Metrics

Overview

  • HQYavne, HM
  • SectorHealth Technology
  • IndustryPharmaceuticals: Major
  • TickerMDWD
  • Price$17.97+5.21%

Trading Information

  • Market Cap$193.83M
  • Float67.04%
  • Average Daily Volume (1m)36,810
  • Average Daily Volume (3m)60,796
  • EPS-$2.16

Company

  • Revenue$20.14M
  • Rev Growth (1yr)6.08%
  • Net Income-$6.31M
  • Gross Margin8.83%
  • EBITDA Margin-81.51%
  • EBITDA-$4.13M
  • EV$122.65M
  • EV/Revenue6.09
  • P/EN/A
  • P/S8.28
  • P/B9.34
Documents
Earnings Calls
Earnings Report 2024Q2
Earnings Report 2024Q1
Earnings Report 2023Q4
Earnings Report (2023-11-21)
Earnings Report (2023-08-16)
Factset Street Account
StreetAccount Earnings Call Q&A Summary: MediWound Q3 ($8.29, -0.27) (2023-11-21T14:55:48Z)
MediWound reports Q3 GAAP EPS ($0.24) vs FactSet ($0.44) [4 est, ($0.57)-(0.36)] ($8.56, 0.00) (2023-11-21T12:06:43Z)
MediWound announces appointment of Shmulik Hess as COO and Chief Commercial Officer, effective as of 1-Dec-23 ($8.56, 0.00) (2023-11-21T12:01:08Z)
MediWound announces agreement with PolyMedics Innovations for distribution of NexoBrid in certain European countries ($7.89, 0.00) (2023-11-08T12:16:01Z)
EU's CHMP adopted a positive opinion recommending a change to the terms of the marketing authorisation for MediWound's NexoBrid ($7.78, 0.00) (2023-11-10T13:12:25Z)